Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 2B (TBC1D2B) is a RAB-specific GTPase-activating protein within the Tre2-Bub2-Cdc16 (TBC) domain-containing superfamily. It interacts principally with RAB5, RAB7, RAB22, and RAB31, key regulators of endosomal and lysosomal trafficking and membrane vesicle dynamics. TBC1D2B is important for the sorting and recycling of membrane proteins, in part through modulating endocytosis and stabilization of E-cadherin at cell junctions, and thus impacts processes such as cell-cell adhesion, epithelial-mesenchymal transition, cell invasion, and metastasis. Germline bi-allelic loss-of-function mutations in TBC1D2B cause a progressive neurodevelopmental disorder with neurologic decline, seizures, gingival overgrowth, and jaw anomalies. In cancer biology, TBC1D2B acts as a negative regulator of invasion and metastasis, partly through suppression of Rab22-induced E-cadherin internalization. There are currently no known drugs that target TBC1D2B, and its role is primarily as a molecular regulator rather than a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1 domain family member 2B (TBC1D2B).